Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 1 for:    NCT01666444
Previous Study | Return to List | Next Study

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Gynecologic Oncology Group
Information provided by (Responsible Party):
VentiRx Pharmaceuticals Inc.
ClinicalTrials.gov Identifier:
NCT01666444
First received: August 10, 2012
Last updated: September 25, 2014
Last verified: September 2014
  Purpose

The purpose of this study is to compare the overall survival of patients treated with VTX-2337 + pegylated liposomal doxorubicin (PLD) versus those treated with PLD alone in women with recurrent or persistent, epithelial ovarian, fallopian tube or primary peritoneal cancer.

VTX-2337, a small molecule agonist of Toll-like Receptor 8 (TLR8), activates multiple components of the innate immune system and is being developed as a novel therapeutic agent for use in oncology. Experimental data obtained in an animal model of ovarian cancer supports the combination of VTX-2337 with PLD. In this model, the combination of VTX-2337 and PLD resulted in a significant reduction in tumor growth compared to either agent alone and an increase in the number of T lymphocytes infiltrating the tumor. The combination of PLD and VTX-2337 has been tested in a small number of women with ovarian cancer in a Phase 1b study and appears to be generally well-tolerated.


Condition Intervention Phase
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
Drug: pegylated liposomal doxorubicin (PLD)
Drug: VTX-2337
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Resource links provided by NLM:


Further study details as provided by VentiRx Pharmaceuticals Inc.:

Primary Outcome Measures:
  • Overall survival (OS) of patients treated with VTX-2337 + PLD versus those treated with PLD alone [ Time Frame: Approximately 15 months after the last patient is randomized. ] [ Designated as safety issue: No ]
    Overall Survival analysis will occur when 146 deaths have occurred.


Secondary Outcome Measures:
  • Progression-free survival (PFS) of patients treated with VTX-2337 + PLD versus those treated with PLD alone using Immune-Related Response Evaluation Criteria In Solid Tumors (irRECIST). [ Time Frame: Approximately 15 months after the last patient is randomized. ] [ Designated as safety issue: No ]
    Progression is assessed at Week 12 and at 8-week intervals thereafter.

  • Frequency and severity of drug-related adverse events (AEs) of patients treated with VTX-2337 + PLD versus those treated with PLD alone. [ Time Frame: Up to 6 months after the last patient is randomized. ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 290
Study Start Date: October 2012
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PLD 40 mg/m2 plus VTX-2337
The dosing schedule will be be based on a 28-day cycle. The starting dose schedule is PLD on Day 1 plus VTX-2337 on Day 3, Day 10, and Day 17 for the first 4 cycles. Starting with cycle 5, the dose regimen will be PLD on Day 1 plus VTX-2337 on Day 3 only, without additional doses of VTX-2337 on Days 10 and Day 17.
Drug: pegylated liposomal doxorubicin (PLD)
Other Names:
  • Doxil
  • Lipodox
Drug: VTX-2337
TLR8 Agonist
Active Comparator: PLD 40 mg/m2 plus placebo
The dosing schedule will be based on a 28-day cycle. The starting dose schedule is PLD on Day 1 plus placebo on Day 3, Day 10, and Day 17 for the first 4 cycles. Starting with cycle 5, the dose regimen will be PLD on Day 1 plus placebo on Day 3 only.
Drug: pegylated liposomal doxorubicin (PLD)
Other Names:
  • Doxil
  • Lipodox
Drug: Placebo

Detailed Description:

OBJECTIVES

Primary Objective:

To compare the overall survival (OS) of patients treated with VTX-2337 + PLD versus those treated with PLD alone in women with recurrent or persistent, epithelial ovarian, fallopian tube or primary peritoneal cancer.

Secondary Objectives:

  • To compare the progression-free survival (PFS) between the two treatment groups using Immune-Related Response Evaluation Criteria In Solid Tumors (irRECIST).
  • To compare the nature, frequency and severity of drug-related adverse events (AEs) between the two treatment groups.

Exploratory Objectives:

  • To compare the best overall response rate (ORR) and duration of response (based on the probability of being in response function [PBRF]) between the two treatment groups using irRECIST.
  • To compare the disease control rate (DCR) between the two treatment groups using irRECIST.
  • To assess the impact of immune status and response on the clinical effects (OS, PFS, DCR, ORR, PBRF, AEs) of study treatment.
  • To assess the effect of TLR8 polymorphisms on the clinical effects (OS, PFS, DCR, ORR, PBRF, AEs) of study treatment.
  • To assess the effect of immune cell subsets, as measured by immunohistochemistry in primary tumor tissue (e.g. immune score), on the clinical effects (OS, PFS, DCR, ORR, PBRF, AEs) of study treatment.

OUTLINE:

This is Phase 2 multicenter clinical study to evaluate the efficacy and safety of the combination of VTX-2337 + PLD compared to PLD + Placebo.

The dosing schedule will be the same for both treatment arms, and will be based on a 28-day cycle. The starting dose schedule is PLD on Day 1 plus VTX-2337 or placebo on Day 3, Day 10, and Day 17 for the first 4 cycles. Starting with cycle 5, the dose regimen will be PLD on Day 1 plus VTX-2337 or placebo on Day 3.

Blood samples are collected periodically during cycle 1 for pharmacodynamics, pharmacogenomics, and other research studies.

Patients will receive therapy until disease progression based on Immune-Related RECIST or until adverse effects prohibit further therapy. Following treatment completion, all patients will be followed with physical exams and histories every three months for the first two years, and then every six months for the next three years, and then

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must have recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
  2. Patients with the following histologic cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial adenocarcinoma, transitional cell carcinoma, malignant Brenner's tumor or adenocarcinoma not otherwise specified.
  3. Patient must have measurable disease as defined by RECIST 1.1.
  4. Patients must have received treatment with a platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin or another organoplatinum compound. This initial treatment may have included intraperitoneal therapy, consolidation, non-cytotoxic agents or extended therapy administered after surgical or non-surgical assessment.

    Patients are allowed to receive, but are not required to receive, one additional cytotoxic regimen for management of recurrent or persistent disease.

    Patients are allowed to have received, but are not required to have received, biologic/targeted therapy (e.g., bevacizumab and/or PARP inhibitor) as part of their primary treatment regimen or for management of recurrent or persistent disease.

  5. Patients must have platinum-resistant disease, defined as having a platinum-free interval (PFI) of < 12 months after first- or second-line platinum-based chemotherapy, or having disease progression while receiving second-line platinum-based chemotherapy.
  6. Patients must have adequate bone marrow, renal, hepatic, and neurologic functions as defined by the following:

    • Bone marrow function: absolute neutrophil count (ANC) ≥ 1,500/mm3. This ANC cannot have been induced or supported by granulocyte colony stimulating factors. Platelets ≥ 100,000/mm3. Hemoglobin ≥ 9 g/dL.
    • Renal function: creatinine ≤ 1.5 x institutional upper limit normal (ULN).
    • Hepatic function: bilirubin < 1.2 mg/dL, SGOT (AST) and SGPT (ALT) ≤ 3.0 x ULN and alkaline phosphatase ≤ 2.5 x ULN.
  7. Patients must have recovered from effects of recent surgery, radiotherapy or chemotherapy:

    • Patients should be free of active infection requiring parenteral antibiotics.
    • Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration. Continuation of hormone replacement therapy is permitted.
    • Any other prior therapy directed at the malignant tumor, including chemotherapy, biologic/targeted agents and immunologic agents, must be discontinued at least three weeks prior to registration.
    • Any prior radiation therapy must be completed at least four weeks prior to registration.
  8. Patients must have a GOG performance status of 0 or 1.
  9. Patients of childbearing potential must have a negative pregnancy test prior to the study entry and be practicing an effective form of contraception. If applicable, patients must discontinue breastfeeding prior to study entry.
  10. Patients must meet the entry requirements and undergo the baseline procedures.
  11. Patients must have signed an IRB-approved informed consent form and authorization permitting release of personal health information.

Exclusion Criteria:

  1. Patients who have had treatment with VTX-2337, doxorubicin, PLD, or any other anthracycline.
  2. Patients who have received an investigational agent < 30 days prior to registration.
  3. Patients who have received oral or parenteral corticosteroids < 2 weeks prior to registration or who require ongoing systemic immunosuppressive therapy for any reason.
  4. Patients with active autoimmune disease. "Active" refers to any condition currently requiring therapy. Examples of autoimmune disease include systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis.
  5. Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of the other malignancy being present within the last three years.
  6. Patients who have received prior radiotherapy OTHER THAN for the treatment of ovarian, fallopian tube or primary peritoneal cancer within the last three years are excluded.
  7. Patients who have received prior chemotherapy OTHER THAN for the treatment of ovarian, fallopian tube or primary peritoneal cancer within the last three years are excluded.
  8. Patients with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study.
  9. Patients with clinically significant cardiovascular disease.
  10. Patients who are pregnant or nursing.
  11. Patients under the age of 18.
  12. Patients with clinical symptoms or signs of gastrointestinal obstruction and/or who require parenteral hydration or nutrition.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01666444

  Hide Study Locations
Locations
United States, Arizona
St. Joseph's Hospital and Medical Center
Phoenix, Arizona, United States, 85013
United States, Arkansas
Winthrop P. Rockefeller Cancer Institute - University of Arkansas
Little Rock, Arkansas, United States, 72205
United States, California
Providence Saint Joseph Medical Center
Burbank, California, United States, 91505
Kaiser Permanente Medical Center
Hayward, California, United States, 94545
Long Beach Memorial Medical Center
Long Beach, California, United States, 90806
Kaiser Permanente Medical Center
Oakland, California, United States, 94611
Kaiser Permanente Medical Center
Roseville, California, United States, 95661
Kaiser Permanente Medical Center
Sacramento, California, United States, 95825
Sutter Cancer Center
Sacramento, California, United States, 95816
Kaiser Permanente Medical Center
San Francisco, California, United States, 94115
Kaiser Permanente Medical Center
San Jose, California, United States, 95119
Kaiser Permanente Medical Center
Santa Clara, California, United States, 95051
Kaiser Permanente Medical Center
South San Francisco, California, United States, 94080
Stanford University School of Medicine
Stanford, California, United States, 94305
Kaiser Permanente Medical Center
Vallejo, California, United States, 94586
Kaiser Permanente Medical Center
Walnut Creek, California, United States, 94596
United States, Colorado
University of Colorado Cancer Center
Aurora, Colorado, United States, 80045
United States, Connecticut
Hartford Hospital
Hartford, Connecticut, United States, 06102
St. Francis Hospital and Medical Center
Hartford, Connecticut, United States, 06105
The Hospital of Central Connecticut
New Britain, Connecticut, United States, 06050
Yale - New Haven Hospital
New Haven, Connecticut, United States, 06520
United States, Florida
MD Anderson Cancer Center - Orlando
Orlando, Florida, United States, 32806
Women's Cancer Associates
St. Petersburg, Florida, United States, 33701
United States, Georgia
Northside Hospital
Atlanta, Georgia, United States, 30342
Georgia Regents University
Augusta, Georgia, United States, 30912
Northeast Georgia Medical Center
Gainesville, Georgia, United States, 30501
Central Georgia Gynecologic Oncology
Macon, Georgia, United States, 31201
St. Joseph's - Candler Gynecologic Oncology
Savannah, Georgia, United States, 31405
Memorial Health University Medical Center
Savannah, Georgia, United States, 31404
United States, Hawaii
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, United States, 96826
United States, Illinois
Northwestern University - Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois, United States, 60611
Rush University Medical Center
Chicago, Illinois, United States, 60612
Sudarshan K. Sharma, MD, LTD
Hinsdale, Illinois, United States, 60521
Carle Cancer Center
Urbana, Illinois, United States, 61801
United States, Indiana
Indiana University Medical Center
Indianapolis, Indiana, United States, 46202
St. Vincent Gynecologic Oncology
Indianapolis, Indiana, United States, 46260
United States, Iowa
McFarland Clinic
Ames, Iowa, United States, 50010
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States, 52242
United States, Kansas
University of Kansas Medical Center
Westwood, Kansas, United States, 66205
United States, Maine
Maine Medical Partners Women's Health
Scarborough, Maine, United States, 04074
United States, Maryland
Greater Baltimore Medical Center
Baltimore, Maryland, United States, 21204
Johns Hopkins Medical Institution
Baltimore, Maryland, United States, 21287
University of Maryland Medical Center
Baltimore, Maryland, United States, 21201
Sinai Hospital of Baltimore
Baltimore, Maryland, United States, 21215
United States, Massachusetts
Lahey Hospital & Medical Center
Burlington, Massachusetts, United States, 01805
University of Massachusetts Memorial Healthcare
Worcester, Massachusetts, United States, 01605
United States, Michigan
St. Joseph Mercy Hospital
Ann Arbor, Michigan, United States, 48106
Bronson Battle Creek
Battle Creek, Michigan, United States, 49017
Karmanos Cancer Institute - Wayne State University
Detroit, Michigan, United States, 48201
Henry Ford Health System
Detroit, Michigan, United States, 48202
Spectrum Health at Butterworth Campus
Grand Rapids, Michigan, United States, 49503
Grand Rapids Clinical Oncology
Grand Rapids, Michigan, United States, 49503
Gynecologic Oncology of West Michigan
Grand Rapids, Michigan, United States, 49546
Saint Mary's Health Care
Grand Rapids, Michigan, United States, 49503
West Michigan Cancer Center
Kalamazoo, Michigan, United States, 49007
Mercy Health Partners - Mercy Campus
Muskegon, Michigan, United States, 49444
Reed City Hospital - Spectrum Health
Reed City, Michigan, United States, 49677
Munson Medical Center
Traverse City, Michigan, United States, 49684
United States, Minnesota
Minnesota Oncology Coon Rapids Clinic
Coon Rapids, Minnesota, United States, 55433
Fairview Southdale Hospital
Edina, Minnesota, United States, 55435
Abbott Northwestern Hospital
Minneapolis, Minnesota, United States, 55404
Metro Minnesota Clinical Oncology Program
St. Louis Park, Minnesota, United States, 55416
Park Nicollet Frauenshuh Cancer Center
St. Louis Park, Minnesota, United States, 55426
Minnesota Oncology Hematology - St. Paul Cancer Center
St. Paul, Minnesota, United States, 55102
Woodbury Clinic - CornerStone Medical Specialty Centre
Woodbury, Minnesota, United States, 55125
United States, Mississippi
St. Dominic-Jackson Memorial Hospital
Jackson, Mississippi, United States, 32916
University of Mississippi Medical Center
Jackson, Mississippi, United States, 39216
United States, Missouri
Ellis Fischel Cancer Center - University of Missouri
Columbia, Missouri, United States, 65211
United States, Nevada
Women's Cancer Care Center of Nevada
Las Vegas, Nevada, United States, 89169
United States, New Hampshire
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
United States, New Jersey
Cooper University Hospital
Camden, New Jersey, United States, 08103
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
United States, New Mexico
University of New Mexico Cancer Center
Albuquerque, New Mexico, United States, 87106
Southwest Gynecologic Oncology Associates
Albuquerque, New Mexico, United States, 87016
Memorial Medical Center
Las Cruces, New Mexico, United States, 88011
United States, New York
Women's Cancer Care Associates
Albany, New York, United States, 12208
SUNY Downstate Medical Center
Brooklyn, New York, United States, 11203
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
Monter Cancer Center
Lake Success, New York, United States, 11042
North Shore University Hospital
Manhasset, New York, United States, 11030
Long Island Jewish Medical Center
New Hyde Park, New York, United States, 11040
Columbia University Medical Center
New York, New York, United States, 10032
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
NYU Langone Medical Center - Cancer Institute
New York, New York, United States, 10016
Gynecologic Oncology of Central New York - SUNY Upstate
Syracuse, New York, United States, 13057
United States, North Carolina
Hope Women's Cancer Center
Asheville, North Carolina, United States, 28806
Alamance Regional Cancer Center
Burlington, North Carolina, United States, 27215
Carolinas Medical Center / Levine Cancer Institute
Charlotte, North Carolina, United States, 28204
Carolinas Medical Center - Northeast
Concord, North Carolina, United States, 28025
Wake Forest University Health Science
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Summa Health System
Akron, Ohio, United States, 44304
University of Cincinnati
Cincinnati, Ohio, United States, 45267
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Fairview Hospital Moll Pavilion Cancer Center
Cleveland, Ohio, United States, 44111
University Hospitals of Cleveland
Cleveland, Ohio, United States, 44106
Ohio State University Medical Center
Columbus, Ohio, United States, 43210
Women's Cancer Center at Kettering Medical Center
Kettering, Ohio, United States, 45429
Hillcrest Hospital - Cleveland Clinic
Mayfield Heights, Ohio, United States, 44124
Lake University Seidman Cancer Center
Mentor, Ohio, United States, 44060
United States, Oklahoma
Peggy and Charles Stephenson Cancer Center
Oklahoma City, Oklahoma, United States, 73104
Tulsa Cancer Institute
Tulsa, Oklahoma, United States, 74146
United States, Pennsylvania
Abington Memorial Hospital; Hanjani Institute for Gynecologic Oncology
Abington, Pennsylvania, United States, 19001
Geisinger Medical Center
Danville, Pennsylvania, United States, 17822
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, United States, 19104
Hillman Cancer Center - University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, United States, 15224
Reading Hospital (McGlinn Family Regional Cancer Center)
West Reading, Pennsylvania, United States, 19611
United States, Rhode Island
Women and Infants Hospital of Rhode Island
Providence, Rhode Island, United States, 02905
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
Bon Secours St. Francis Hospital
Greenville, South Carolina, United States, 29601
Gibbs Cancer Center
Spartanburg, South Carolina, United States, 29303
United States, South Dakota
Avera Cancer Institute
Sioux Falls, South Dakota, United States, 57105
United States, Texas
UT Southwestern Medical Center
Dallas, Texas, United States, 75390
University of Texas Medical Branch
Galveston, Texas, United States, 77555
MD Anderson Cancer Center
Houston, Texas, United States, 77030
The Methodist Hospital
Houston, Texas, United States, 77030
United States, Utah
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States, 84112
United States, Virginia
Mid Atlantic Pelvic Surgery Associates
Annandale, Virginia, United States, 22003
Virginia Gynecology Oncology
Richmond, Virginia, United States, 23229
Carilion Clinic Gynecological Oncology
Roanoke, Virginia, United States, 24016
United States, Washington
Northwest Hospital - UW Medicine
Seattle, Washington, United States, 98133
Pacific Gynecology Specialists
Seattle, Washington, United States, 98104
Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109
University of Washington Medical Center
Seattle, Washington, United States, 98195
Women's Cancer Care of Seattle
Seattle, Washington, United States, 98133
United States, Wisconsin
Green Bay Oncology at St. Mary's Hospital
Green Bay, Wisconsin, United States, 54303
Green Bay Oncology at St. Vincent's Hospital
Green Bay, Wisconsin, United States, 54301
St Vincent Hospital
Green Bay, Wisconsin, United States, 54301
University of Wisconsin-Madison
Madison, Wisconsin, United States, 53792
Holy Family Memorial Medical Center
Manitowoc, Wisconsin, United States, 54221
Bay Area Medical Center
Marinette, Wisconsin, United States, 54143
Marshfield Clinic
Marshfield, Wisconsin, United States, 54449
Aurora St. Luke's Medical Center Gynecologic Oncology
Milwaukee, Wisconsin, United States, 53215
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Aspirus Regional Cancer Center
Wausau, Wisconsin, United States, 54401
Sponsors and Collaborators
VentiRx Pharmaceuticals Inc.
Gynecologic Oncology Group
Investigators
Study Chair: Bradley J. Monk, MD St. Joseph's Hospital and Medical Center, Phoenix AZ
  More Information

No publications provided

Responsible Party: VentiRx Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT01666444     History of Changes
Other Study ID Numbers: GOG-3003
Study First Received: August 10, 2012
Last Updated: September 25, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by VentiRx Pharmaceuticals Inc.:
recurrent epithelial ovarian cancer
recurrent fallopian tube cancer
recurrent primary peritoneal cavity cancer
ovarian serous cystadenocarcinoma
ovarian endometrioid adenocarcinoma
ovarian mucinous cystadenocarcinoma
ovarian undifferentiated adenocarcinoma
ovarian clear cell cystadenocarcinoma
ovarian mixed epithelial carcinoma
Brenner tumor

Additional relevant MeSH terms:
Fallopian Tube Neoplasms
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Peritoneal Neoplasms
Abdominal Neoplasms
Adnexal Diseases
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Fallopian Tube Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Ovarian Diseases
Peritoneal Diseases
Urogenital Neoplasms
Doxorubicin
Liposomal doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Topoisomerase II Inhibitors
Topoisomerase Inhibitors

ClinicalTrials.gov processed this record on November 24, 2014